BioAdaptives SEC Filings

Tip
Raport
Dată
4Insidertransaktion03.03.2026
4Insidertransaktion03.02.2026
4Insidertransaktion05.01.2026
4Insidertransaktion03.12.2025
10-QQuartalsbericht14.11.2025
4Insidertransaktion04.11.2025
4Insidertransaktion06.10.2025
4Insidertransaktion03.09.2025
10-QQuartalsbericht14.08.2025
4Insidertransaktion05.08.2025
4Insidertransaktion03.07.2025
4Insidertransaktion03.06.2025
4Insidertransaktion23.05.2025
10-QQuartalsbericht13.05.2025
4Insidertransaktion05.05.2025
33-Formular05.05.2025
10-KJahresbericht15.04.2025
NT 10-KNT 10-K-Formular31.03.2025
DEF 14CDEF 14C-Formular28.03.2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben18.03.2025
DEF 14CDEF 14C-Formular14.03.2025
SEC STAFF ACTIONSEC STAFF ACTION-Formular24.02.2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben07.02.2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben05.12.2024
4Insidertransaktion03.12.2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben27.11.2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben20.11.2024
10-QQuartalsbericht19.11.2024
NT 10-QNT 10-Q-Formular14.11.2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben30.10.2024
SC 13DSC 13D-Formular22.10.2024
SC 13DSC 13D-Formular22.10.2024
10-QQuartalsbericht19.08.2024
NT 10-QNT 10-Q-Formular15.08.2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben22.05.2024
10-QQuartalsbericht17.05.2024
NT 10-QNT 10-Q-Formular15.05.2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben14.05.2024
10-KJahresbericht10.04.2024
NT 10-KNT 10-K-Formular01.04.2024
10-QQuartalsbericht13.11.2023
1-A1-A-Formular11.10.2023
1-Z1-Z-Formular24.08.2023
10-QQuartalsbericht11.08.2023
10-QQuartalsbericht12.05.2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben06.04.2023
10-KJahresbericht31.03.2023
DEF 14CDEF 14C-Formular28.03.2023
PRE 14CPRE 14C-Formular09.03.2023
QUALIFQUALIF-Formular17.11.2022
CORRESPCORRESP-Formular15.11.2022
10-QQuartalsbericht14.11.2022
1-A POS1-A POS-Formular08.11.2022
UPLOADUPLOAD-Formular31.10.2022
1-A POS1-A POS-Formular28.10.2022
CORRESPCORRESP-Formular28.10.2022
UPLOADUPLOAD-Formular20.10.2022
1-A POS1-A POS-Formular07.10.2022
10-QQuartalsbericht12.08.2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben14.06.2022
253G1253G1-Formular16.05.2022
10-QQuartalsbericht12.05.2022
QUALIFQUALIF-Formular11.05.2022
CORRESPCORRESP-Formular09.05.2022
1-A/A1-A/A-Formular03.05.2022
10-KJahresbericht31.03.2022
UPLOADUPLOAD-Formular30.03.2022
1-A/A1-A/A-Formular18.03.2022
UPLOADUPLOAD-Formular16.03.2022
DEF 14CDEF 14C-Formular15.03.2022
1-A1-A-Formular04.03.2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben03.02.2022
PRE 14CPRE 14C-Formular27.01.2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben21.01.2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben16.12.2021
10-QQuartalsbericht10.11.2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben27.08.2021
10-QQuartalsbericht12.08.2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben22.07.2021
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11.06.2021
10-QQuartalsbericht14.05.2021
10-KJahresbericht30.03.2021
10-QQuartalsbericht16.11.2020
10-QQuartalsbericht13.08.2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben16.06.2020
10-Q/A10-Q/A-Formular11.06.2020
10-QQuartalsbericht10.06.2020
10-K/A10-K/A-Formular12.05.2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11.05.2020
10-KJahresbericht01.05.2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben30.03.2020
DEF 14CDEF 14C-Formular04.03.2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11.02.2020
PRE 14CPRE 14C-Formular10.02.2020
10-QQuartalsbericht07.11.2019
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben27.09.2019
10-QQuartalsbericht14.08.2019
UPLOADUPLOAD-Formular01.08.2019
10-12G/A10-12G/A-Formular23.07.2019
UPLOADUPLOAD-Formular10.07.2019

BioAdaptives Documente 2026

Această pagină conține toate documentele oficiale și depunerile SEC pentru acțiunea BioAdaptives (BDPT, ISIN: US09072U2069). Aceasta include rapoarte anuale (Form 10-K), rapoarte trimestriale (Form 10-Q) și tranzacții interne (Form 4). În prezent sunt disponibile 100 documente. Datele sunt actualizate regulat pentru a oferi investitorilor o prezentare generală completă a depunerilor de reglementare ale BioAdaptives.

BioAdaptives Analiza acțiunilor

BioAdaptives BioAdaptives Inc, trading under the ticker symbol BDPT, is a corporate entity incorporated in the United States with its principal headquarters located in Las Vegas, Nevada. The company formally entered the public markets through an initial public offering on July 9, 2014. Despite its public listing, the organization operates with a notably lean workforce, currently employing only one full-time individual. The firm identifies itself as a multifaceted enterprise engaged in research, development, marketing, and educational activities, primarily targeting the health and wellness sector. Its strategic focus is directed toward the creation and distribution of products designed to enhance human biological function and overall well-being. The company’s portfolio includes dietary supplements and specialty food items, alongside proprietary methods aimed at optimizing the bioelectromagnetic availability of foods and beverages. This technical approach underpins its broader mission to deliver solutions that address specific physiological and cognitive challenges. The intellectual property and product base of BioAdaptives Inc are engineered to provide benefits such as improved cognition, enhanced focus, reduction of fatigue, increased testosterone levels, and better emotional and physical wellness. Furthermore, the company positions its offerings as aids in healing and anti-aging processes. A significant component of its commercial strategy involves a product agreement with Ferris Holding, Inc., commonly referred to as Ferris. Under this arrangement, BioAdaptives holds the rights to develop, market, and sell specific products, notably PrimiCell and PrimiLive. Beyond these established items, the company is actively advancing other product lines. Two products, Equine Regen and Equine Regen Plus, are currently in the advanced stages of testing, indicating a potential expansion into the animal health market. The company also offers PrimiTrim, a product specifically designed for weight control, as well as an exercise product. Additionally, development efforts are underway for a new product intended for dogs, suggesting a diversification strategy that extends beyond human nutraceuticals into the broader pet care sector. The company’s official online presence is maintained at http://www.bioadaptives.com/, where further details regarding its educational initiatives and product specifications may be found. The firm’s operational model relies heavily on its intellectual property assets and strategic partnerships to navigate the competitive landscape of the health and wellness industry, leveraging its small team to manage research, development, and marketing efforts for its diverse range of devices and nutraceuticals.